# FGFR Inhibitor ET0111 Monotherapy in Patients With Advanced Solid Tumors

> **NCT05522309** · PHASE1 · UNKNOWN · sponsor: **Etern BioPharma (Shanghai) Co., Ltd** · enrollment: 37 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** ET0111

## Key facts

- **NCT ID:** NCT05522309
- **Lead sponsor:** Etern BioPharma (Shanghai) Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-30
- **Primary completion:** 2024-12-01
- **Final completion:** 2025-05-01
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2022-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05522309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05522309, "FGFR Inhibitor ET0111 Monotherapy in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05522309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*